You have 9 free searches left this month | to do more
Showing 1 - 25 of
40 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
Recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Hamburg, Germany
  • +4 more
2021-12-20
Dec 20, 2021
C
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia.
Recruiting
  • Beta-Thalassemia
  • Los Angeles, California
  • +7 more
2021-06-03
Jun 3, 2021
M
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Recruiting
  • Myelodysplastic Syndromes
  • Miami, Florida
  • +5 more
2021-11-10
Nov 10, 2021
M
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Recruiting
  • Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2022-01-19
Jan 19, 2022
C
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
Active, not recruiting
Has Results
  • Thalassemia
  • Luspatercept
  • +2 more
  • Los Angeles, California
  • +13 more
2021-10-18
Oct 18, 2021
G
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Not yet recruiting
  • MDS
  • Myelodysplastic Syndromes
  • Luspatercept Injection [Reblozyl]
  • Eprex
  • Amiens, France
  • +28 more
2021-12-20
Dec 20, 2021
C
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Chiba, Japan
  • +18 more
2022-01-08
Jan 8, 2022
C
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Active, not recruiting
  • Primary Myelofibrosis
  • Anemia
  • Luspatercept
  • Phoenix, Arizona
  • +23 more
2022-01-10
Jan 10, 2022
C
A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions
Recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Beijing, China
  • +23 more
2022-02-03
Feb 3, 2022
A
ACE-536 Extension Study - Myelodysplastic Syndromes - 2020
Completed
  • Myelodysplastic Syndromes
  • Dresden, Germany
    Acceleron Investigative Site
2021-04-29
Apr 29, 2021
A
Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) - 2018
Completed
  • Anemia
  • Dresden, Germany
    Acceleron Investigative Site
2021-04-29
Apr 29, 2021
C
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Aurora, Colorado
  • +34 more
2022-02-16
Feb 16, 2022
A
ACE-536 Extension Study - Beta Thalassemia - 2020
Completed
  • Beta-Thalassemia
  • Athens, Greece
  • +6 more
2021-05-17
May 17, 2021
C
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia - 2021
Completed
Has Results
  • Erythrocyte Transfusion
  • Beta-Thalassemia
  • Luspatercept
  • Placebo
  • Los Angeles, California
  • +72 more
2022-01-21
Jan 21, 2022
C
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes - 2020
Completed
Has Results
  • Myelodysplastic Syndromes
  • Luspatercept
  • Placebo
  • Stanford, California
  • +73 more
2021-11-19
Nov 19, 2021
C
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Recruiting
  • Myelodysplastic Syndromes (MDS)
  • +2 more
  • Luspatercept
  • Los Angeles, California
  • +121 more
2020-11-30
Nov 30, 2020
C
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Recruiting
  • Myeloproliferative Disorders
  • +4 more
  • La Jolla, California
  • +149 more
2022-03-18
Mar 18, 2022
C
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Epoetin alfa
  • Birmingham, Alabama
  • +239 more
2022-03-15
Mar 15, 2022
N
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy - 2022
Completed
  • Acute Myelogenous Leukemia
  • +6 more
  • This is a non-interventional study
  • Bakersfield, California
  • +19 more
2022-04-04
Apr 4, 2022
I
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS TMPRSS6-LRx
Active, not recruiting
  • Beta Thalassemia Intermedia
  • IONIS TMPRSS6-LRx
  • Camperdown, New South Wales, Australia
  • +20 more
2022-01-03
Jan 3, 2022
T
Safety of SP-420 in the Treatment of Transfusional Iron Overload
Recruiting
  • Iron Overload
  • San Antonio, Texas
    Mays Cancer Center, UT Health San Antonio
2021-06-22
Jun 22, 2021
C
Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)
Not yet recruiting
  • Myelodysplastic Syndromes
  • Beta-thalassemia
    • (no location specified)
    2021-07-13
    Jul 13, 2021
    M
    A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
    Recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Basking Ridge, New Jersey
    • +5 more
    2022-02-14
    Feb 14, 2022
    T
    Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
    Recruiting
    • Leukemia
    • +2 more
    • Enasidenib mesylat dose escalation
    • Palo Alto, California
      Stanford Cancer Institute
    2022-03-07
    Mar 7, 2022
    R
    Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
    Not yet recruiting
    • Low Risk Myelodysplastic Syndromes
    • R906289 Monosodium (R289 Na)
    • (no location specified)
    2022-03-25
    Mar 25, 2022